/SLXN
SLXN Stock - Silexion Therapeutics Ltd.
Healthcare|BiotechnologyNASDAQ
$2.40-1.23%
$0.03 (-1.23%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.64
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SLXN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.38 – $2.42
TARGET (TP)$2.76
STOP LOSS$2.21
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.06
52W High$51.75
52W Low$2.13
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-12,571,000 | $-4,681,000 | $-3,860,000 | $-943,933 | $-195,860 |
| Net Income | $-16,443,000 | $-4,942,000 | $-3,215,000 | $-755,218 | $-195,860 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.64 | $-4.42 | $0.03 | $-0.05 | $-0.01 |
Company Overview
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SLXNBeat Rate
20%
Last 5 quarters
Avg Surprise
-772.1%
EPS vs Estimate
Beats / Misses
1/4
Last 12 quarters
Latest EPS
$-2.88
Q4 2025
EPS Surprise History
Q3 24
No data
Q4 24
-147.6%
$-18.27vs$-7.38
Q1 25
-2018.4%
$-20.76vs$-0.98
Q2 25
-1672.7%
$-3.90vs$-0.22
Q3 25
-37.1%
$-4.32vs$-3.15
Q4 25
+15.3%
$-2.88vs$-3.40
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 17, 2026 | $-1.17 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-3.40 | $-2.88 | +15.3% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-3.15 | $-4.32 | -37.1% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.22 | $-3.90 | -1672.7% | ✗ MISS |
Q1 2025 | Mar 18, 2025 | $-0.98 | $-20.76 | -2018.4% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-7.38 | $-18.27 | -147.6% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | — | $-0.99 | — | — |
Q2 2024 | May 15, 2024 | — | — | — | — |
Latest News
Silexion Therapeutics Submits Regulatory Application To Israel For Its Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic Cancer
📈 PositiveBenzinga•Dec 16, 2025, 01:41 PM
Litchfield Hills Initiates Coverage On Silexion Therapeutics with Buy Rating, Announces Price Target of $6
📈 PositiveBenzinga•Dec 15, 2025, 02:45 PM
Silexion Therapeutics Receives Written Scientific Advice From German Regulator Regarding Proposed Design Of Phase 2/3 Clinical Study For SIL204 For Locally Advanced Pancreatic Cancer
➖ NeutralBenzinga•Dec 2, 2025, 01:04 PM
Silexion Therapeutics Completes SIL204 Toxicology Studies Ahead Of Planned Phase 2/3 Trial
📈 PositiveBenzinga•Nov 25, 2025, 02:18 PM
Silexion Therapeutics Q3 EPS $(2.88) Beats $(3.40) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 02:04 PM
Silexion Therapeutics Says SIL204 Demonstrates Activity Against Eleven Human Cell Lines Originating From 5 Different Organ Cancer Sites, Each With Specific KRAS Mutation
📈 PositiveBenzinga•Sep 30, 2025, 12:41 PM
Silexion Therapeutics Files For Mixed Shelf Of Up To $100M
➖ NeutralBenzinga•Sep 26, 2025, 08:34 PM
Silexion Therapeutics Regains Nasdaq Compliance
📈 PositiveBenzinga•Sep 25, 2025, 12:46 PM
Silexion Therapeutics announces pricing of $6M public offering
➖ NeutralSeeking Alpha•Sep 11, 2025, 01:33 PM
Silexion Therapeutics Prices $6M Public Offering Of 1.5M Shares And Warrants At A Combined Price Of $4.00
➖ NeutralBenzinga•Sep 11, 2025, 01:18 PM
Market-Moving News for September 11th
➖ NeutralBenzinga•Sep 11, 2025, 11:26 AM•Also: ,
Silexion Highlights Preclinical Data Of SIL204 Supporting Dual-Route Treatment Strategy With Phase 2/3 Trial On Track For 2026
📈 PositiveBenzinga•Sep 11, 2025, 11:07 AM
Silexion's SIL204 Reaches All Major Sites Of Pancreatic Cancer Spread And Cuts Tumor Burden In Preclinical Study
📈 PositiveBenzinga•Sep 11, 2025, 11:01 AM
Silexion Therapeutics Selects A Contract Research Organization AMS Advanced Medical Services GmbH To Support SIL204 Phase 2/3 Trials Targeting KRAS Cancers, Following 97% Inhibition Rates; Trials Expected To Begin 1H 2026
📈 PositiveBenzinga•Sep 4, 2025, 01:28 PM
Frequently Asked Questions about SLXN
What is SLXN's current stock price?
Silexion Therapeutics Ltd. (SLXN) is currently trading at $2.40 per share. The stock has moved -1.23% today.
What is the analyst price target for SLXN?
No analyst price targets are currently available for this stock.
What sector is Silexion Therapeutics Ltd. in?
Silexion Therapeutics Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SLXN's market cap?
Silexion Therapeutics Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does SLXN pay dividends?
No, Silexion Therapeutics Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZTR
Azitra, Inc.
$0.29
Mkt Cap: $0.0B
ENVB
Enveric Biosciences, Inc.
$5.08
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
ONCO
Onconetix, Inc.
$1.77
Mkt Cap: $0.0B
PTIX
Protagenic Therapeutics, Inc.
$1.19
Mkt Cap: $0.0B
SCNI
Scinai Immunotherapeutics Ltd.
$0.79
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SPRC
SciSparc Ltd.
$1.46
Mkt Cap: $0.0B
Explore stocks similar to SLXN for comparison